“This marks another important win for Senzime in the US market as we continue to expand our installed base and lead the technology conversion to safer anesthesia. IDNs play a central role in the US healthcare system, often making centralized purchasing decisions that can extend across hundreds of affiliated hospitals. Adoption is driven not only by patient safety considerations, but also by the need to reduce anesthesia drug costs, minimize complications, and ensure compliance with evolving clinical guidelines,” comments Philip Siberg, CEO of Senzime.

Senzime’s solutions are used by anesthesiologists in thousands of operating rooms worldwide to enhance patient safety during and after surgery. The TetraGraph^® system uses proprietary algorithms and advanced sensors to monitor the electrical activity of patients’ muscles during surgery. The monitor helps clinicians optimize dosing of neuromuscular blocking and reversal agents as well as help determine when it is safe to intubate patients and restore spontaneous breathing after surgery.

TetraGraph is designed to support compliance with recent clinical guidelines published by anesthesiology societies, including the American Society of Anesthesiologists (ASA) and European Society of Anaesthesiology and Intensive Care (ESAIC).